RxDoctor Payments Data

Jorge Pereira, MD

Urology · Miami Beach, FLNPI 1962701599

Payments from drug & device makers

$8,216in general payments, 2019–2025

Across 161 payments — averaging $51.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Avyxa Pharma, LLC$3K
  • Boston Scientific$905
  • Myriad Genetic Laboratories, Inc.$570
  • Astellas Pharma US Inc$478
  • Coloplast$329
  • EDAP Technomed Inc$283
  • plus $2K from 36 others

What the payments were for

  • Speaking & faculty fees$2,00024%
  • Travel & lodging$91011%
  • Food & beverage$5,07562%
  • Education$2323%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,216 in reported general payments places this provider in the 65th percentile of 935 urology providers in Florida.

See all urology providers in Florida

Medicare billing

Part B allowed, 2024
$82,148
Medicare patients
222
Services billed
858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron133$113,643
OrgovyxRelugolix19$50,853
MyrbetriqMirabegron66$47,568
ElmironPentosan Polysulfate Sodium11$10,971
Silodosin81$10,424
Testosterone29$5,543
Tamsulosin Hcl441$4,079
Tadalafil35$4,001
Potassium Citrate ErPotassium Citrate26$3,110
Alfuzosin Hcl ErAlfuzosin Hcl53$1,319
Finasteride126$1,221
Methenamine Hippurate11$1,104
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst17$581
Ciprofloxacin Hcl74$350
Sildenafil Citrate80$328

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$98$164,496152 claims
Astellas Pharma US IncMyrbetriq$478$47,56866 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 935 urology providers in Florida.

Other urology in Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →